Hematopoietic stem cell transplant (HCT) recipients have a substantial risk of developing
secondary solid cancers, particularly beyond 5 years after HCT and without reaching a …

Introduction: Although human papillomavirus (HPV) routine vaccination programmes have
been implemented around the world and recommendations have been expanded to include …

Risks of secondary solid cancers among allogeneic hematopoietic cell transplant (HCT)
recipients who receive conditioning without total body irradiation are not well known. We …

At mucosal sites, papillomavirus genomes can persist in the epithelial basal layer following
immune-mediated regression. Subsequent T-cell depletion stimulates a 3-to 5-log increase …

More than 25 000 allogeneic hematopoietic stem cell transplantations (allo-HCTs) are
expected to be performed worldwide in 2010, a number that has been increasing yearly …

The presence of viral DNA in the absence of disease has suggested that papillomaviruses,
like many other viruses, can exist as latent infections in the skin or other epithelial sites. In …

Despite similarities relevant age-and gender-specific issues exist in the care of patients after
allogeneic hematopoietic SCT (HSCT). Female genital chronic GVHD (cGVHD) has been …

Subsequent neoplasms (SN) after hematopoietic cell transplantation (HCT) cause significant
patient morbidity and mortality. Risks for specific SN types vary substantially, with particularly …

Secondary cancers that arise in allogeneic haematopoietic‐cell transplant recipients,
possibly as a result of treatment exposures, are a relatively rare complication of …

Organ transplant recipients (OTRs) are at increased risk of developing nonmelanoma skin
cancers. This has long been thought to be caused by immunosuppression and viral …